Baricitinib 4 MG Oral Tablet

DRUG5 trials

Sponsors

Fabrizio Cantini, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, University of Alabama at Birmingham, I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio, University Hospital, Brest

Conditions

COVIDCalcium Pyrophosphate Deposition DiseaseChondrocalcinosisFrontal Fibrosing AlopeciaPneumoniaPolymyalgia Rheumatica (PMR)Rheumatoid Arthritis

Phase 2

Baricitinib Therapy in COVID-19

CompletedNCT04358614

Fabrizio CantiniCOVID, Pneumonia

Start: 2020-03-16End: 2020-04-07Updated: 2020-04-24

Baricitinib in CPPD - the BAPTIST Study

Not yet recruitingNCT06768294

I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioCalcium Pyrophosphate Deposition Disease, Chondrocalcinosis

Start: 2025-01-31End: 2027-01-31Target: 32Updated: 2025-01-10

Phase 3

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

Not yet recruitingNCT07279688

University Hospital, BrestPolymyalgia Rheumatica (PMR)

Start: 2025-12-12End: 2029-06-12Target: 140Updated: 2025-12-12

Phase 4

Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

CompletedNCT05660655

Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshRheumatoid Arthritis

Start: 2022-10-01End: 2023-09-30Updated: 2023-11-18

A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Active, not recruitingNCT06240351

University of Alabama at BirminghamFrontal Fibrosing Alopecia

Start: 2024-04-22End: 2027-07-31Target: 15Updated: 2026-01-30

Related Papers

Baricitinib in moderate to severe rheumatoid arthritis: dose-dependent efficacy and safety in a randomized clinical trial in a developing country

BMC Rheumatology2026-03-30